<DOC>
	<DOCNO>NCT01020331</DOCNO>
	<brief_summary>Tau , protein cerebrospinal fluid CSF believe elevated amyotrophic lateral sclerosis ( ALS ) patient . The investigator believe Tau truly marker increase neuronal death disease process . It show Memantine inhibit reverse abnormal hyperphosphorylation Tau therefore investigator look efficacy Memantine 10 mg twice day ( BID ) see disease progression correlate possible change Tau ALS patient base ALS Functional Rating Scale ( ALSFRS ) score .</brief_summary>
	<brief_title>Memantine Therapy Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>We interested role develop active anti-excitotoxic cocktail patient ALS . As part interest investigate potential marker disease progression . One candidate marker presence elevate level TAU CSF patient ALS . While presence Tau originally describe used adjunctive diagnostic testing patient Alzheimer 's disease become clear many neurodegenerative disease possess elevate level Tau CSF . Therefore Tau truly marker increase neuronal death disease process . While level Tau study depth ALS , one report 2003 show 70 % ALS patient elevate level Tau CSF ( Sussmuth et al ) . We also collect series 24 patient clinically definite ALS find 22 elevated level Tau time diagnosis . We intrigue finding Memantine , NMDA receptor antagonist , inhibit reverse abnormal hyperphosphorylation Tau lead sequestration normal Tau microtubule well microtubule associate protein 1 ( MAP-1 ) MAP-2 . Further , Memantine show block disassembly microtubule follow hyperphosphorylation Tau ( Li et al. , 2004 ) . We submit presentation International Motor Neuron Disease meeting 2005 data two anecdotal case patient ALS . These two patient diagnosed ALS clinical electrophysiological data find elevated level Tau CSF time diagnosis . Both patient treat Riluzole , standard therapy , Memantine 10 mg BID 6 month . After 6 month disease course clearly slow . A repeat analysis CSF show level Tau return normal .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Inclusion Criteria 1 . Age 1885 2 . Male Female 3 . Clinically definite ALS El Escorial criterion 4 . Elevated level Tau CSF 1 . Patients FVC 1.5 L require respiratory assistance 2 . History liver disease 3 . Severe renal failure 4 . History intolerance Riluzole Memantine 5 . Any co morbid condition would make completion trial unlikely 6 . If female , pregnant breastfeeding ; , childbearing age , unwillingness use birth control . 7 . Taking trial medication . Nontrial medication cause exclusion . 8 . Unwillingness provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>ALS</keyword>
</DOC>